Discover the power of real-time signals plus AI
Every contract, funding round, exec hire, and M&A move on KORRO BIO, INC. — with verified, ICP-scored contact reveals (email + mobile) on demand.
Trusted by founders, sales teams, recruiters, and investors at firms like BlackRock, Oracle, Kleiner Perkins, and HubSpot.
Korro Bio Collaborates with Novo Nordisk to Develop Two Therapeutic Candidates
Contract Type
partnership
CambridgeDescription
Korro Bio, Inc. has announced a partnership with Novo Nordisk to advance the discovery and development of new genetic medicines, with the initial target to treat cardiometabolic diseases. The collaboration aims to leverage Korro’s proprietary OPERATM platform to enable oligonucleotide-directed RNA edits into two undisclosed targets, with a total deal value of up to $530 million in upfront, development, and commercial milestone payments, in addition to tiered royalties and R&D funding.